Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis.

In the control group, whereas patients who received SCT had longer OS and PFS than those who did not receive SCT, this did not reach statistical significance, likely due to the relatively small sample size (Figure 2D ).

also in 111,027 other papers